Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M775Revenue $M3.4Net Margin (%)-178.3Z-Score-1.5
Enterprise Value $M739EPS $-0.8Operating Margin %-161.2F-Score3
P/E(ttm))0Cash Flow Per Share $-0.5Pre-tax Margin (%)-178.3Higher ROA y-yY
Price/Book45.110-y EBITDA Growth Rate %-24.9Quick Ratio7.0Cash flow > EarningsN
Price/Sales23.45-y EBITDA Growth Rate %-11.8Current Ratio7.1Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-41.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)-273.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M123ROI % (ttm)-167.3Gross Margin Increase y-yN

Gurus Latest Trades with OREX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
OREXJohn Burbank 2013-12-31 Sold Out -0.15%$4.72 - $6.83
($5.61)
$ 6.2912%Sold Out0
OREXJohn Burbank 2012-09-30 Buy 0.2%$3.77 - $7.39
($5.32)
$ 6.2918%New holding, 750000 sh.750,000
OREXGeorge Soros 2012-06-30 Sold Out -0.03%$3.16 - $6.37
($3.76)
$ 6.2967%Sold Out0
OREXGeorge Soros 2012-03-31 Buy 0.03%$1.68 - $5.01
($3.11)
$ 6.29102%New holding, 500000 sh.500,000
OREXJean-Marie Eveillard 2010-09-30 Sold Out -0.01%$3.9 - $6.77
($4.98)
$ 6.2926%Sold Out0
OREXJean-Marie Eveillard 2010-06-30 Add$4.05 - $7.04
($5.57)
$ 6.2913%Add 74.07%470,000
OREXJean-Marie Eveillard 2010-03-31 Add$5.9 - $7.66
($6.55)
$ 6.29-4%Add 22.73%270,000
OREXJean-Marie Eveillard 2009-12-31 Add0.01%$6.44 - $9.39
($7.57)
$ 6.29-17%Add 83.33%220,000
OREXJean-Marie Eveillard 2009-09-30 Buy 0.01%$5.2 - $10.34
($7.89)
$ 6.29-20%New holding, 120000 sh.120,000
OREXBill Gates 2009-06-30 Sold Out $1.89 - $5.21
($3.19)
$ 6.2997%Sold Out0
OREXJean-Marie Eveillard 2007-09-30 Sold Out $13.21 - $15.88
($14.5)
$ 6.29-57%Sold Out0
OREXJean-Marie Eveillard 2007-06-30 Buy $13.75 - $17.94
($16)
$ 6.29-61%New holding, 21400 sh.21,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

OREX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


OREX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Turner Heather DSVP, Gen. Counsel & Secretary 2014-12-02Sell22,643$64.83view
Turner Heather DSVP, Gen. Counsel & Secretary 2014-11-25Sell31,388$5.837.89view
BOCK LOUIS CDirector 2014-11-18Buy1,325$5.5812.72view
BOCK LOUIS CDirector 2014-11-12Buy27,052$5.5712.93view
Turner Heather DVP, Gen. Counsel & Secretary 2014-09-22Sell300,000$4.4740.72view
NARACHI MICHAELPresident and CEO 2014-09-15Buy50,000$4.7831.59view
Hagan Joseph PSr. VP, Corporate Development 2014-09-15Buy5,000$4.6934.12view
Hagan Joseph PChief Business Officer 2013-07-31Sell12,000$7.8-19.36view
Hagan Joseph PChief Business Officer 2013-07-26Sell10,000$7.4-15view
Booth Mark DChief Commercial Officer 2013-07-26Sell64,767$7.55-16.69view

Press Releases about OREX :

    Quarterly/Annual Reports about OREX:

    News about OREX:

    Articles On GuruFocus.com
    Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
    Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
    Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
    Arena Facing Increased Pressure from Peers Apr 23 2012 
    Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
    Vivus Could Rocket on Success of Qnexa Apr 13 2012 
    Steve Cohen Bets On Orexigen Ahead of FDA Approval Jan 31 2011 
    Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2010 
    Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
    cooldecency99 note on OREX May 01 2010 


    More From Other Websites
    Nasdaq stocks posting largest percentage increases Dec 18 2014
    Six Biotech and Technology Stocks With Strong Technical Set-Ups Dec 18 2014
    Bio-Twitter Sentiment Favors European Orexigen Obesity Pill Approval Dec 17 2014
    Obesity Pill Upstart Orexigen Therapeutics Gaining on Rivals Dec 12 2014
    These 4 Biotech Stocks Have Been On Fire Dec 08 2014
    Why Orexigen Therapeutics (OREX) Stock Might be a Great Pick Dec 05 2014
    Earnings Estimates Moving Higher for Orexigen (OREX): Time to Buy? Dec 03 2014
    Orexigen Therapeutics to Present at the Piper Jaffray Healthcare Conference Nov 26 2014
    Orexigen Therapeutics to Present at the Piper Jaffray Healthcare Conference Nov 26 2014
    Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl... Nov 21 2014
    Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl... Nov 21 2014
    Is Orexigen Really Worth Over 50% More? Nov 19 2014
    OREXIGEN THERAPEUTICS, INC. Financials Nov 18 2014
    2 Skyrocketing Biotech Stocks In A Stalling Market Nov 17 2014
    Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind Nov 14 2014
    What's Driving Orexigen Therapeutics Higher? Nov 13 2014
    10-Q for Orexigen Therapeutics, Inc. Nov 12 2014
    A ho-hum day in the markets as stocks open weaker, but recover to close mixed... Nov 12 2014
    Orexigen Therapeutics Continues To Rally Nov 12 2014
    Orexigen Turns Around with Q3 Earnings Beat, Shares Soar Nov 11 2014
    Today's Perilous Reversal Stock: Orexigen Therapeutics (OREX) Nov 11 2014
    Orexigen (OREX) Worth Watching: Stock Soars 33.3% Nov 11 2014
    Orexigen Therapeutics (OREX) Stock Continues to Rise as EU Reviews Contrave Drug Nov 10 2014
    Orexigen rises as weight loss drug review proceeds Nov 10 2014
    Orexigen rises as weight loss drug review proceeds Nov 10 2014
    Orexigen Therapeutics (OREX) Stock Soars Today on Big Third Quarter Earnings Beat Nov 10 2014
    Orexigen Therapeutics Reports Results for the Third Quarter Ended September 30, 2014 Nov 10 2014
    Orexigen Therapeutics to Present at the Credit Suisse Healthcare Conference Nov 06 2014
    Orexigen Therapeutics to Host Third Quarter 2014 Financial Results Conference Call and Webcast Nov 04 2014
    Orexigen Announces Contrave® (naltrexone HCI and bupropion HCI extended release) Data Presentations... Oct 31 2014
    Takeda and Orexigen Announce Availability of CONTRAVE® (naltrexone HCI and bupropion HCI)... Oct 20 2014
    Milestone Payments Earned by Orexigen Total $100 Million as Contrave® (naltrexone HCI and bupropion... Oct 15 2014
    Shire eating disorder drug gets U.S. priority review Sep 15 2014
    FDA approves weight-loss drug Contrave Sep 11 2014
    Orexigen falls on further FDA delays for diet pill Jun 11 2014
    Ahead of the Bell: Orexigen Therapeutics slips Jun 11 2014
    MARKET PULSE-Biofuel, Orexigen, Rambus, Synaptics Jun 11 2014
    Orexigen Therapeutics Reports Corporate and Financial Results for the Fourth Quarter and Year Ended... Mar 12 2014
    Orexigen Therapeutics to Host Full Year and Fourth Quarter 2013 Financial Results Conference Call... Mar 03 2014
    Orexigen Provides Update on Its NB32 European Marketing Authorization Application Feb 25 2014
    Orexigen Therapeutics to Present at Upcoming Investor Conferences Feb 06 2014
    Orexigen Announces June 10, 2014 PDUFA Action Date for Contrave Jan 07 2014
    Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference Jan 06 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK